You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Developing Active Stimulation and Monitoring Technologies to Optimize Pain and Nociception Management During Regional Anesthesia, General Anesthesia, and Post-Operative Care
SBC: PASCALL Systems, Incorporated Topic: 106Project Summary Surgery and acute post-operative pain are major contributors to persistent pain, chronic pain, and opioid dependence. Currently, there are no products on the market in the United States that can be used to monitor surgical nociception. Existing products use indicators that are susceptible to intraoperative influences such as blood loss, anesthetic drugs and antihypertensives. This ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Novel Combinations of Natural Product Compounds for Treatment of Alzheimer Disease and Related Dementias
SBC: Path Biotech, LLC Topic: NIAPROJECT SUMMARY/ABSTRACT In response to National Institute on Aging's (NIA) strategic plan and PAS-19-317, we propose novel therapeuticsto treat Alzheimer disease and related dementias (ADRDs). We have developed novel combinations of three natural product compounds, which modulate complementary pathways in multiple types of CNS cells (i.e., neurons, microglia) associated with AD pathology. These c ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Controlled Gradient Release of Biologics: Enhanced Nerve Conduit for Long‐Gap Injury Repair
SBC: Pioneer Neurotech Inc. Topic: 106Project Summary / Abstract Nerve injuries arising from trauma, disease, or as a surgical necessity, lead most often to permanent loss of some or all functions mediated by the injured nerves. 50,000 peripheral nerve procedures are performed every year in the US, and 300,000 across Europe. After complete transection of a nerve, the optimal clinical procedure for nerve repair remains the surgical end ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
ICU-CARE: An interactive mobile app to enhance the efficiency of daily informal caregiving in the intensive care unit
SBC: SILICON CURES LLC Topic: NINRPROJECT SUMMARY Actively involving informal caregivers in direct patient care at the bedside in the intensive care unit (ICU) has the potential to improve patient, informal caregiver, and health care system outcomes. Practice guidelines call for the liberal inclusion of informal caregivers as active partners in ICU care, but there is a critical, unmet need to develop tools that effectively operati ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy
SBC: OASIS PHARMACEUTICALS, LLC Topic: NHLBIDespite prevalent use of anti-platelet and anti-lipid therapies, stroke remains the third major cause of death and is the leading cause of adult disability in the US with an estimated cost in the range of $34 billion annually. Approximately 20% of the annual 795,000 stroke patients die within one year and 15-30% are permanently disabled. Antiplatelet therapy is mainly used for primary prevention o ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Targeted ColQ gene therapy for Congenital Myasthenic Syndromes
SBC: Amplo Biotechnology, Inc. Topic: 106PROJECT SUMMARY Congenital Myasthenic Syndromes (CMS) are a group of clinically similar neuromuscular transmission disorders that differ in their underlying genetic mutation. While some phenotypical variation exists, CMS are commonly characterized by muscle weakness (myasthenia) that worsens with physical exertion. Defects in Collagen Q (ColQ), a multidomain functional protein of the Neuro Muscula ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Inducible HMGB1 antagonist for viral-induced acute lung injury.
SBC: SIGMOVIR BIOSYSTEMS, INC. Topic: NHLBIFor more than a decade, our work has focused on development of therapeutic interventions for viral- and bacterial-induced acute lung injury (ALI) and the more severe acute respiratory distress syndrome (ARDS). Significantly, we identified the Toll-like receptor 4 (TLR4) signaling pathway as key to the host response to influenza and secondary bacterial infection following influenza. We also identif ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a portable beat-to-beat fetal ECG system
SBC: AUSCULTECH DX LLC Topic: NICHDProject Summary There are 24,000 stillbirths per year in the United States, and 2.6 million stillbirths per year worldwide, with no significant decrease in the last decade. Abnormal fetal heart rhythms, such as long QT syndrome, are thought to play an important role in these deaths, and may cause 3- 10% of unexplained stillbirths. This is in addition to known fetal arrhythmias, which affect 1-3% o ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a novel sensor for the real-time measurement of mitral coaptation force
SBC: MitralPint Inc. Topic: NHLBIProject Summary The proposed project will develop a breakthrough endovascular sensor technology to allow for real-time quantification of the mitral coaptation force (MCF) of the mitral valve during both open and percutaneous mitral valve repair (MVR). Mitral regurgitation (MR) is the most common heart valve disorder in the U.S. population, with over 2 million individuals affected. Current methods ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
An Efficacy Trial of Mobile Technology for Reducing and Preventing Adolescent Suicide
SBC: OUI THERAPEUTICS INC Topic: 104ABSTRACT Suicide is a leading cause of death in the US and suicide rates have steadily increased. Despite this, there is a paucity of interventions that reduce suicide ideation and behavior. In this project, we seek to enhance a beta version of our suicide prevention digital therapeutic (developed in phase I) and conduct a randomized controlled trial to evaluate the efficacy of the digital therape ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health